VIDEO: Safety education on atopic dermatitis treatments key to effective management

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

So I'm a great believer in educational events to patients and to caregivers. Many times, I think caregivers are not up-to-date and also are not up-to-date with the safety. For example, biologics like Dupilumab and Tralokinumab, they have great safety.

They don't require monitoring, blood monitoring. Very important to know that and to convey that to the patient. So it's very important to know what you are dealing with and what is the safety in the population when you treat a disease. The same with JAK inhibitors, we need to realize that the safety of JAK inhibitors in patients with atopic dermatitis is better than, for example, their safety in a disease like rheumatoid arthritis, where you are dealing with a different population, right?

These are older patients. Many times they have other comorbid diseases. So very important to think about that and know who your population are. I am usually not giving JAK inhibitors for patients that are over 65 because it was shown the JAK inhibitors have a less favorable safety profile in that population. So you need to think about what population you have, their desires, whether they are fine with an injection, they want an oral, and so on.